What to Expect Your First Month on a GLP-1

The first month on a GLP-1 is about adjustment, not dramatic weight loss. Both semaglutide and tirzepatide start at intentionally low doses designed to let your body adapt, which means the early weeks feel different than most people expect. Quieter appetite, some manageable side effects, modest movement on the scale. Here is what actually happens, week by week, so nothing catches you off guard.

The Quick Answer

Most people lose 2 to 3% of their body weight in the first four weeks on a GLP-1, based on head-to-head trial data.³ The first month runs on a starter dose: 0.25 mg weekly for semaglutide or 2.5 mg weekly for tirzepatide.¹² Appetite typically quiets within the first week or two. Mild nausea is common in the 24 to 48 hours after an injection and usually fades as your body adjusts. The dose typically increases at week 5, though your provider may adjust the starting dose and pace based on your history and tolerance.

Before Your First Injection

A medically supervised program should establish a baseline before you inject anything. That means recent bloodwork, a review of your medical history, and ideally a body composition measurement, since tracking fat versus muscle matters more than tracking total pounds.

Your provider should also screen for the conditions that rule these medications out. Both semaglutide and tirzepatide carry a boxed warning against use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.¹² A history of pancreatitis, current pregnancy, or plans to become pregnant also change the conversation. If a program skips these questions, that is a red flag about the program, not a green light for you.

Week 1: The First Injection

Both medications are once-weekly subcutaneous injections, typically into the abdomen, thigh, or upper arm. The needle is small, and most people are surprised by how little they feel.

Your starting dose is deliberately low. Semaglutide begins at 0.25 mg weekly and tirzepatide at 2.5 mg weekly, and per FDA labeling these are initiation doses rather than therapeutic maintenance doses.¹² The point of month one is building tolerance so the rest of the protocol goes smoothly. These are the standard starting points for first-time patients. If you are switching from another GLP-1 or restarting after a break, your provider may start you at a different dose based on your history.

The most common first-week experience is a quieter relationship with food. GLP-1 receptor agonists slow gastric emptying and act on appetite centers in the brain, which many patients describe as the "food noise" turning down. Cravings lose volume. Fullness arrives sooner and stays longer.

Mild nausea in the 24 to 48 hours after the first injection is common and usually passes on its own. Some people notice a headache or fatigue. Many people notice nothing at all, which is normal too. A quiet first week does not mean the medication is not working.

Week 2: Appetite Gets Quiet

By the second injection, appetite suppression usually becomes noticeable in daily life. You sit down to a normal plate and stop halfway through. Snacking between meals drops off without effort.

This is the week to build the habits that determine how well the next six months go. Two priorities stand out. First, protein. Eating less overall means it is easy to under-eat protein, and adequate protein may help protect your muscle while the fat comes off. Research presented at ENDO 2025 found that higher protein intake may help preserve lean mass during GLP-1 treatment,⁸ and many clinicians target at least 1.2 g per kg of body weight daily. Second, water. Slower gastric emptying plus reduced intake makes dehydration and constipation more likely, and both are easier to prevent than fix.

Week 3: Managing Side Effects

If GI side effects show up, weeks 2 through 4 are when they tend to make themselves known. In the STEP 1 trial of semaglutide, nausea affected 44% of participants, constipation 23%, and diarrhea 32% over the full 68-week study, with most events rated mild to moderate and concentrated during dose escalation.⁴ Tirzepatide reported lower nausea rates, between 25% and 33% depending on dose, across SURMOUNT-1.⁵

The pattern matters more than the percentages: side effects cluster in the days right after an injection or a dose increase, then fade.⁶ What helps is mostly mechanical. Smaller meals. Slower eating. Stopping at the first signal of fullness instead of finishing the plate. Limiting greasy, fried, or very rich foods on injection days. Fiber and fluids for constipation.

Energy can dip this week as your calorie intake drops. That is your cue to check protein intake, not push through on willpower. If you strength train, keep doing it. Resistance training plus adequate protein is the best-studied combination for preserving muscle on these medications.⁸ Read: How to Protect Muscle Mass on a GLP-1.

Week 4: The Scale and Your First Titration Decision

Here is what the data says about month one. In SURMOUNT-5, the first head-to-head trial of the two medications, participants had lost about 2% of body weight on semaglutide and 3% on tirzepatide by week 4.³ For someone starting at 220 pounds, that is roughly 4 to 7 pounds. Real, but modest by design, because you have spent the month on the lowest dose.

Early response is encouraging but not destiny in either direction. Post hoc analyses suggest faster early losers tend to lose more by the end of treatment, while many slower starters still reach clinically meaningful weight loss as the dose escalates.⁷ One month of data is a starting point, not a verdict.

Week 4 is also decision time. Per FDA labeling, semaglutide steps up to 0.5 mg and tirzepatide to 5 mg after four weeks, but only if you are tolerating the current dose.¹² If side effects are still loud, staying at the current dose for longer is a legitimate medical decision. The labeled schedule is a framework, and a supervising provider should adjust the pace to your tolerance, labs, and response. This is exactly why frequent provider check-ins during titration matter: the schedule should bend to your biology, not the other way around.

First-Month Side Effects at a Glance

Most GI events in the trials were mild to moderate, and discontinuation due to side effects was uncommon: under 5% at tirzepatide's 5 mg dose and 6 to 8% at higher doses.⁵⁶

When to Call Your Provider

Most first-month side effects are an annoyance, not an emergency. A few are not. Contact your provider promptly for severe abdominal pain that may radiate to your back (a possible sign of pancreatitis), persistent vomiting or inability to keep fluids down, signs of dehydration such as dizziness or dark urine, severe pain in the upper right abdomen (a possible gallbladder issue), or symptoms of an allergic reaction.¹² If you have diabetes and take other glucose-lowering medications, watch for hypoglycemia and report vision changes.

This list is why "medically supervised" should mean more than a prescription and a refill link. Someone should be checking in on you, especially during titration.

Common Questions

Last updated June 11, 2026.